JP2020514280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514280A5 JP2020514280A5 JP2019534814A JP2019534814A JP2020514280A5 JP 2020514280 A5 JP2020514280 A5 JP 2020514280A5 JP 2019534814 A JP2019534814 A JP 2019534814A JP 2019534814 A JP2019534814 A JP 2019534814A JP 2020514280 A5 JP2020514280 A5 JP 2020514280A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer cells
- cells
- lymphocyte
- kit
- fdimp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 31
- 210000004698 lymphocyte Anatomy 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 210000004881 tumor cell Anatomy 0.000 claims 7
- 229940044665 STING agonist Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000003308 immunostimulating effect Effects 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 102000009123 Fibrin Human genes 0.000 claims 2
- 108010073385 Fibrin Proteins 0.000 claims 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 101000802471 Sylvirana guentheri Brevinin-2GHb Proteins 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229950003499 fibrin Drugs 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 229950008737 vadimezan Drugs 0.000 claims 2
- XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 claims 2
- QSPOQCXMGPDIHI-UHFFFAOYSA-N 2-amino-n,n-dipropyl-8-[4-(pyrrolidine-1-carbonyl)phenyl]-3h-1-benzazepine-4-carboxamide Chemical compound C1=C2N=C(N)CC(C(=O)N(CCC)CCC)=CC2=CC=C1C(C=C1)=CC=C1C(=O)N1CCCC1 QSPOQCXMGPDIHI-UHFFFAOYSA-N 0.000 claims 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108010079458 CBLB502 Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- KUFRQPKVAWMTJO-LMZWQJSESA-N alvespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C1C2=O KUFRQPKVAWMTJO-LMZWQJSESA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229950009493 entolimod Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000002313 intestinal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000010453 lymph node cancer Diseases 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 claims 1
- 229910001000 nickel titanium Inorganic materials 0.000 claims 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 108700002563 poly ICLC Proteins 0.000 claims 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000010409 thin film Substances 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 239000012646 vaccine adjuvant Substances 0.000 claims 1
- 229940124931 vaccine adjuvant Drugs 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022097810A JP2022130502A (ja) | 2016-12-21 | 2022-06-17 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2023012548A JP7595099B2 (ja) | 2016-12-21 | 2023-01-31 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2024168197A JP2025013785A (ja) | 2016-12-21 | 2024-09-27 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437572P | 2016-12-21 | 2016-12-21 | |
| US62/437,572 | 2016-12-21 | ||
| PCT/US2017/067965 WO2018119274A1 (en) | 2016-12-21 | 2017-12-21 | Scaffolds to treat solid tumor cells and escape variants |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022097810A Division JP2022130502A (ja) | 2016-12-21 | 2022-06-17 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2023012548A Division JP7595099B2 (ja) | 2016-12-21 | 2023-01-31 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020514280A JP2020514280A (ja) | 2020-05-21 |
| JP2020514280A5 true JP2020514280A5 (enExample) | 2021-02-04 |
| JP7295360B2 JP7295360B2 (ja) | 2023-06-21 |
Family
ID=62627587
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534814A Active JP7295360B2 (ja) | 2016-12-21 | 2017-12-21 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2022097810A Pending JP2022130502A (ja) | 2016-12-21 | 2022-06-17 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2023012548A Active JP7595099B2 (ja) | 2016-12-21 | 2023-01-31 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2024168197A Pending JP2025013785A (ja) | 2016-12-21 | 2024-09-27 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022097810A Pending JP2022130502A (ja) | 2016-12-21 | 2022-06-17 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2023012548A Active JP7595099B2 (ja) | 2016-12-21 | 2023-01-31 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
| JP2024168197A Pending JP2025013785A (ja) | 2016-12-21 | 2024-09-27 | 固形腫瘍細胞及びエスケープバリアントを治療するための足場 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US20190336532A1 (enExample) |
| EP (2) | EP4371584A3 (enExample) |
| JP (4) | JP7295360B2 (enExample) |
| CN (2) | CN110167566A (enExample) |
| WO (1) | WO2018119274A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014110591A1 (en) | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| CA3073919A1 (en) * | 2017-08-30 | 2019-03-07 | Beijing Xuanyi Pharmasciences Co., Ltd. | Cyclic di-nucleotides as stimulator of interferon genes modulators |
| US10493233B1 (en) * | 2018-06-05 | 2019-12-03 | Duke University | Bi-directional access to tumors |
| EP3966222A4 (en) | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
| CN113456810A (zh) * | 2020-03-30 | 2021-10-01 | 杭州星鳌生物科技有限公司 | 一种新型抗新冠病毒治疗性疫苗及其制备方法和应用 |
| AU2021270750B2 (en) * | 2020-05-13 | 2024-06-13 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
| WO2024081898A1 (en) * | 2022-10-13 | 2024-04-18 | North Carolina State University | Implantable scaffolds and methods of use |
| US20250101358A1 (en) * | 2023-07-21 | 2025-03-27 | Systemic Bio, Llc | Human vascularized integrated organ system and applications thereof |
| WO2025166113A1 (en) * | 2024-02-01 | 2025-08-07 | Fred Hutchinson Cancer Center | Cell-free implants for in vivo recruitment, activation, and reprogramming of immune cells |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA181413A (en) | 1917-02-06 | 1918-01-01 | Frank Dyehe Law | Tire |
| US4078052A (en) | 1976-06-30 | 1978-03-07 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Large unilamellar vesicles (LUV) and method of preparing same |
| CH624011A5 (enExample) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| CH621479A5 (enExample) | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4241046A (en) | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US20020062154A1 (en) * | 2000-09-22 | 2002-05-23 | Ayers Reed A. | Non-uniform porosity tissue implant |
| WO2005112974A2 (en) | 2004-05-14 | 2005-12-01 | William Marsh Rice University | Peptide-modified polyurethane compositions and associated methods |
| US8936650B2 (en) * | 2011-03-23 | 2015-01-20 | The Regents Of The University Of California | Mesh enclosed tissue constructs |
| US9925296B2 (en) * | 2011-03-23 | 2018-03-27 | The Regents Of The University Of California | Mesh enclosed tissue constructs |
| EP2701686A4 (en) * | 2011-04-28 | 2014-11-05 | Stc Unm | LIPID BINCHES SUPPORTED ON POROUS NANOPARTICLES (PROTOCELLS) FOR TARGETED ADMINISTRATION, AND METHODS OF USE THEREOF |
| WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
| WO2014110591A1 (en) * | 2013-01-14 | 2014-07-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| CA2928532A1 (en) * | 2013-10-23 | 2015-04-30 | Nsvascular, Inc. | Three-dimensional thin-film nitinol devices |
| WO2015077354A1 (en) * | 2013-11-19 | 2015-05-28 | The University Of Chicago | Use of sting agonist as cancer treatment |
| WO2016079899A1 (ja) * | 2014-11-20 | 2016-05-26 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途 |
| US20170340658A1 (en) * | 2014-12-16 | 2017-11-30 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
| JO3746B1 (ar) * | 2015-03-10 | 2021-01-31 | Aduro Biotech Inc | تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون" |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| US20180117171A1 (en) * | 2015-04-01 | 2018-05-03 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
-
2017
- 2017-12-21 EP EP23215104.3A patent/EP4371584A3/en active Pending
- 2017-12-21 EP EP17883391.9A patent/EP3558327A4/en active Pending
- 2017-12-21 US US16/472,764 patent/US20190336532A1/en not_active Abandoned
- 2017-12-21 JP JP2019534814A patent/JP7295360B2/ja active Active
- 2017-12-21 CN CN201780079628.7A patent/CN110167566A/zh active Pending
- 2017-12-21 CN CN202510482074.1A patent/CN120324623A/zh active Pending
- 2017-12-21 WO PCT/US2017/067965 patent/WO2018119274A1/en not_active Ceased
-
2022
- 2022-06-17 JP JP2022097810A patent/JP2022130502A/ja active Pending
- 2022-06-22 US US17/846,391 patent/US20220339195A1/en active Pending
-
2023
- 2023-01-31 JP JP2023012548A patent/JP7595099B2/ja active Active
- 2023-09-28 US US18/476,774 patent/US20240033293A1/en not_active Abandoned
-
2024
- 2024-09-27 JP JP2024168197A patent/JP2025013785A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514280A5 (enExample) | ||
| Alkayyal et al. | NK-cell recruitment is necessary for eradication of peritoneal carcinomatosis with an IL12-expressing Maraba virus cellular vaccine | |
| Musetti et al. | Nanoparticle-mediated remodeling of the tumor microenvironment to enhance immunotherapy | |
| JP7457899B2 (ja) | 修飾された免疫細胞及びその使用 | |
| Weiden et al. | Synthetic immune niches for cancer immunotherapy | |
| Chan et al. | Aggressive T/natural killer cell lymphoma presenting as testicular tumor | |
| Tzeng et al. | In situ genetic engineering of tumors for long-lasting and systemic immunotherapy | |
| CN108392633B (zh) | Pcsk9抑制剂在恶性肿瘤免疫治疗中的应用 | |
| CN112969793A (zh) | 经修饰的t细胞、其制备方法及用途 | |
| Malla et al. | mRNA vaccines and their delivery strategies: a journey from infectious diseases to cancer | |
| Jinesh G et al. | Bladder cancer stem cells: biological and therapeutic perspectives | |
| Lee et al. | CCL7 signaling in the tumor microenvironment | |
| Bottai et al. | Progress in nonviral gene therapy for breast cancer and what comes next? | |
| CN112654346B (zh) | 生物分子包覆颗粒和薄膜及其用途 | |
| Yu et al. | T cell immunotherapy for cervical cancer: challenges and opportunities | |
| Conti et al. | Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB‐neuT Mice | |
| Bodles-Brakhop et al. | DNA vaccination and gene therapy: optimization and delivery for cancer therapy | |
| Cho et al. | An optimized peptide vaccine strategy capable of inducing multivalent CD8+ T cell responses with potent antitumor effects | |
| Hutzler et al. | Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles | |
| León-Letelier et al. | Induction of progenitor exhausted tissue-resident memory CD8+ T cells upon salmonella Typhi Porins adjuvant immunization correlates with Melanoma control and anti-PD-1 immunotherapy cooperation | |
| Ten et al. | Tumor microenvironment modulation by cancer-derived extracellular vesicles | |
| Bolm et al. | Multimodal anti-tumor approaches combined with immunotherapy to overcome tumor resistance in esophageal and gastric cancer | |
| Inoue et al. | Identification of SPARC as a candidate target antigen for immunotherapy of various cancers | |
| Mujahid et al. | Biomaterial-based sustained-release drug formulations for localized cancer immunotherapy | |
| Sun et al. | IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys |